Sensyne Health Plc (LON: SENS) has signed a five-year non-exclusive SRA (Strategic Research Agreement) with Milton Keynes University Hospital NHS Foundation Trust (MKUH).

  • The agreement with MKUH will facilitate the ethical application of clinical AI research to enhance patient care and step up research into new medicines.
  • As per the agreement, MKUH will get 1,428,571 ordinary shares in the company representing 1.1 per cent of the existing issued share capital.
  • The company also has SRAs with South Warwickshire NHS Foundation Trust, Wye Valley and George Eliot NHS Trusts, Chelsea & Westminster Hospitals NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust.
  • On 26 October 2020, the stocks of the company surged by 5.66% from its previous closing, hovering at around GBX 112.00 at 08:13 AM GMT+1.



The website is a service of Kalkine Media Ltd, Company Number 12643132. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK